When was Qixin Biotechnology founded?

Qixin Biotechnology was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Qixin Biotechnology located?

Qixin Biotechnology is headquartered in Hangzhou, China.

How many employees does Qixin Biotechnology have?

As of Jul 01, 2024, the latest employee count at Qixin Biotechnology is 51 - 200.

Is Qixin Biotechnology a funded company?

Qixin Biotechnology is a funded company, having raised a total of $116M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 23, 2018.

When was the latest funding round of Qixin Biotechnology?

Qixin Biotechnology's latest funding was a $***** Series A round on Sep 22, 2023, with participation from 1 investor. Its primary sector is Genomics. In China, the Genomics sector has seen $119M in funding in 2026 to date.

Where does Qixin Biotechnology rank among its competitors?

Qixin Biotechnology ranks 15th amongst 123 active competitors, of which 60 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Scribe Therapeutics, which secured $25M in Jun, 2026.

Who are the top competitors of Qixin Biotechnology?

Qixin Biotechnology's top competitors include Beam Therapeutics, eGenesis and Mammoth. Among them, Scribe Therapeutics secured the most recent funding round in June, 2026.

Qixin Biotechnology - 2026 Company Profile, Team, Funding & Competitors

Qixin Biotechnology is a series A company based in Hangzhou (China), founded in 2017 by George Church and Luhan Yang. It operates as a Provider of gene-editing technology for therapies. Qixin Biotechnology has raised $116M in funding from investors like Sequoia Capital, CMB International Capital and Lilly Asia Ventures. The company has 123 active competitors, including 60 funded and 13 that have exited. Its top competitors include companies like Beam Therapeutics, eGenesis and Mammoth.

Company Details

Provider of gene-editing technology for therapies. The company uses this platform of genetic engineering for developing tools for organ transplantation and regenerative medicines. It uses CRISPR/Cas9 system as a gene-editing tool.

Website: www.qihanbio.com
Email ID: *****@qihanbio.com
Phone Number: +86 **********

Key Metrics

Founded Year

2017

Location

Hangzhou, China

Stage

Series A

Total Funding

$116M in 4 rounds

Latest Funding Round

Series A, Sep 22, 2023, $*****

Investors

Sequoia Capital & 11 more

Ranked

15^th among 123 active competitors

Employee Count

51 - 200 as on Jul 01, 2024

Similar Companies

Beam Therapeutics & 138 more

View Qixin Biotechnology's full profile

Qixin Biotechnology has raised a total funding of $116M over 4 rounds. Its first funding round was on Jul 23, 2018. Its latest funding round was a Series A round on Sep 22, 2023 for $*****. 1 investor participated in its latest round. Qixin Biotechnology has 12 institutional investors.

Here is the list of recent funding rounds of Qixin Biotechnology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 22, 2023	1874706	Series A	5683658	9169585	6716164	6948594
Mar 29, 2021	5995722	Series A	9957237	3157808	5205242	Sequoia Capital & 1 more
Sep 23, 2019	7081480	Series A	5012465	4494640	CMB International Capital	Legend Star & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Qixin Biotechnology's funding rounds and investors

The founders of Qixin Biotechnology are George Church and Luhan Yang.

Here are the details of Qixin Biotechnology's key team members:

George Church: Co-Founder of Qixin Biotechnology.
Luhan Yang: Co-Founder of Qixin Biotechnology.

View details of Qixin Biotechnology's Founder profiles and Board Members

Qixin Biotechnology's employee count trend

Qixin Biotechnology has 51 - 200 employees as of Jul 24. Here is Qixin Biotechnology's employee count trend over the years:

Employee count trend for Qixin Biotechnology

Uncover Qixin Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Qixin Biotechnology include Beam Therapeutics, eGenesis and Mammoth. Here is the list of Top 10 competitors of Qixin Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	F-Prime Capital, Cormorant-asset & 16 others	71/100
2nd	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$481M	Samsara BioCapital, Monashee Investment Management ... & 30 others	65/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, NFX & 34 others	65/100
4th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, SymBiosis & 22 others	64/100
5th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
6th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	T. Rowe Price, F-Prime Capital & 10 others	64/100
7th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	T. Rowe Price, ADIA & 22 others	63/100
8th	Scribe Therapeutics 2018, Alameda (United States), Public	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 7 others	62/100
9th	Kytopen 2017, Cambridge (United States), Series B	Developer of gene delivery systems for cell therapy	$44.5M	Northpond Ventures, Horizons Ventures & 12 others	61/100
10th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Eclipse, Decheng Capital	60/100
15th	Qixin Biotechnology 2017, Hangzhou (China), Series A	Provider of gene-editing technology for therapies	$116M	Biomatics Capital, Arch Venture Partners ... & 10 others	56/100